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Abstract Atherosclerosis is the main cause of morbidity
and mortality in diabetes, yet the underlying mechanisms
remain unclear. Retention of atherogenic lipoproteins by
vascular proteoglycans is thought to play a key role in the
development of atherosclerotic lesions. High glucose levels
cause a variety of diabetic complications by several mecha-
nisms, including upregulation of the hexosamine pathway.
Glucosamine, a component of the hexosamine pathway, is a
precursor for the synthesis of glycosaminoglycan compo-
nents of proteoglycans. This study evaluated whether high
glucose or glucosamine supplementation of vascular smooth
muscle cells would increase proteoglycan synthesis, leading
to increased lipoprotein retention. Aortic smooth muscle
cells were exposed to physiologic (5.6 mM) or high (25
mM) glucose levels, such as seen in diabetes, or to glu-
cosamine (12 mM). Extracellular proteoglycans were char-
acterized by sulfate incorporation, molecular sieve chroma-
tography, and SDS-PAGE. LDL interactions were assessed
by affinity chromatography and gel mobility shift assay. Pro-
teoglycans synthesized in the presence of high glucose dem-
onstrated no differences in size, sulfate incorporation, or
LDL binding affinity compared with proteoglycans synthe-
sized under physiological glucose conditions. However, pro-
teoglycans synthesized in the presence of glucosamine had
smaller glycosaminoglycan chains than control proteogly-
cans with a corresponding decrease in lipoprotein reten-
tion.  Thus, glucose and glucosamine have different ef-
fects on proteoglycan biosynthesis and different effects on
lipoprotein retention.
 
—Tannock, L. R., P. J. Little, T. N.
Wight, and A. Chait.
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Proteoglycans are a heterogeneous group of molecules
that occur ubiquitously in the arterial wall. The major se-
creted extracellular vascular proteoglycans are the large
 
chondroitin sulfate proteoglycan versican, and the small
dermatan sulfate proteoglycans biglycan and decorin (1,
2). Alterations in proteoglycan concentrations and com-
position have been found focally in prelesional and le-
sional areas of atherosclerosis in diabetes (3, 4). The “re-
sponse to retention” hypothesis of atherosclerosis states
that proteoglycans bind and retain LDL in the subendo-
thelial compartment. Retention of LDL by arterial pro-
teoglycans has been suggested to increase the susceptibil-
ity of the LDL to modifications such as oxidation (5–8).
Proteoglycans bind lipoproteins via interactions between
negatively charged sulfate and carboxyl groups on their
glycosaminoglycan side chains and positively charged amino
acid residues on apolipoproteins B and E. Therefore,
changes in the size or charge of proteoglycans or their gly-
cosaminoglycan chains might have significant effects on
their lipoprotein-binding properties (9, 10).
Glucosamine is a precursor in the synthesis of gly-
cosaminoglycan chains. Glucosamine is gaining popular-
ity as an over-the-counter supplement for arthritis and has
been shown to improve joint pain and joint space narrow-
ing in the knees (11). Glucosamine supplementation leads
to increased glycosaminoglycan and proteoglycan synthe-
sis in cartilage (12, 13), which has been proposed to ac-
count for improved symptoms.
Glucosamine also is a component of the hexosamine
pathway, which has been demonstrated to be a mecha-
nism by which glucose leads to diabetic complications
(14). In the hexosamine pathway, glucose is metabolized
to hexosamine via the transfer of an amide group from
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glutamine to fructose 6-phosphate to form glucosamine
6-phosphate. This subsequently is metabolized to hex-
osamines such as UDP-
 
N
 
-acetylglucosamine (UDP-GlcNAc)
and UDP-
 
N
 
-acetylgalactosamine, which are the building
blocks for glycosaminoglycan synthesis (15). The rate-
limiting step in the hexosamine pathway is the initial
transfer of the amide group from glutamine, which is cata-
lyzed by the enzyme glutamine:fructose-6-phosphate ami-
dotransferase (GFAT; EC 2.6.1.16) (14). GFAT activity is
upregulated by high glucose and insulin levels (16), and is
downregulated by UDP-GlcNAc (17). Under euglycemic
conditions only 2–3% of glucose fluxes through the hex-
osamine pathway; however, the flux through this pathway
is likely to be increased in the presence of hyperglycemia
(18). Glucosamine enters the hexosamine pathway distal to
the rate-limiting step, and therefore bypasses GFAT. Glu-
cosamine, and the hexosamine pathway, have been found
to be associated with increased synthesis of extracellular
matrix proteoglycans in mesangial cells (19). The present
study was performed to determine 
 
a
 
) the effect of glu-
cosamine on the synthesis of extracellular proteoglycans
by vascular smooth muscle cells, and 
 
b
 
) the ability of the
secreted proteoglycans to bind lipoproteins. The study
also evaluated whether the effects of glucosamine are me-
diated through the hexosamine pathway.
RESEARCH DESIGN AND METHODS
 
Chemicals and reagents were obtained from Sigma (St. Louis,
MO) unless otherwise specified.
 
Cell culture techniques
 
Arterial smooth muscle cells isolated from monkey (
 
Macaca
nemestrina
 
) thoracic aortas were plated at a density of 2.5 
 
3
 
 10
 
5
 
cells per 60-mm dish and grown to confluence in commercially
available DMEM with 5.6 mM glucose, supplemented with pyru-
vate, nonessential amino acids, penicillin (10
 
5
 
 U/l), strepto-
mycin (10
 
5
 
 
 
m
 
g/l), glutamine, and 5% calf serum. Cells were used
between passages 6 and 18 and culture medium was changed
every 48 to 72 h. Cells reaching visual confluence were made
quiescent for 48 h by lowering the serum concentration to 0.1%.
Quiescent cells were exposed to high (25 mM) or physiologic
(5.6 mM) concentrations of glucose for 24 h in the presence of
5% serum. Cells were metabolically labeled with 
 
35
 
SO
 
4
 
 (50–100
 
m
 
Ci/ml) or [
 
35
 
S]methionine (10–20 
 
m
 
Ci/ml) during this 24-h
period. After removal of the radiolabeled culture medium the
cell layer was washed once with PBS and then cell protein was de-
termined by the method of Lowry et al (20). Parallel dishes were
treated in an identical fashion except without 
 
35
 
SO
 
4
 
 labeling,
and cells were washed with PBS, trypsinized, and counted in a
Coulter counter. Cell count and cell protein determination were
performed on duplicate aliquots per dish, and in duplicate
dishes per condition. Cytotoxicity was assessed by determining
lactate dehydrogenase (LDH) activity of the medium [cytoxicity
detection kit (LDH); Boehringer Mannheim, Indianapolis, IN].
In addition, the incorporation of [
 
35
 
S]methionine into total cell
protein was determined using total trichloroacetic acid (TCA)-
precipitable counts (21).
Quiescent cells were supplemented with glucosamine (12
mM) added to DMEM containing 5.6 mM glucose. Glucosamine
enters the cell through glucose transporters and is rapidly phos-
phorylated by hexokinase to glucosamine 6-phosphate. To test
the role of the hexosamine pathway, quiescent cells were ex-
posed to high glucose (25 mM) DMEM, or to high glucose me-
dium in the presence of the GFAT inhibitor azaserine (5 
 
m
 
M)
(14). Cells were exposed to these conditions for 24 h in the pres-
ence of 5% serum, and were metabolically labeled under these
conditions, as described earlier. Time course studies were per-
formed by exposing quiescent cells to physiologic glucose (5.6
mM) or various concentrations of glucosamine (0.12, 1.2, or 12
mM) for 8, 16, or 24 h in the presence of 
 
35
 
SO
 
4
 
 for the last 8 h of
incubation.
 
Proteoglycan isolation
 
Media from metabolically labeled cell cultures were collected
and the protease inhibitors benzamidine-HCl (5 mM), 6-amino-
caproic acid (100 mM), and phenylmethylsulfonyl fluoride (50
mM) were added immediately. Media from replicate dishes were
pooled and frozen at 
 
2
 
70
 
8
 
C for 1 to 3 days. The secreted pro-
teoglycans synthesized under the different experimental condi-
tions were concentrated on separate DEAE-Sephacel minicol-
umns equilibrated with 8 M urea buffer (8 M urea, 2 mM EDTA,
50 mM Tris-HCl, 0.5% Triton X-100, pH 7.5) with 0.25 M
NaCl, and were eluted in 4 M guanidine-HCl buffer including
100 mM sodium sulfate, 100 mM Tris base, and 2.5 mM EDTA,
pH 7.4.
 
Hydrodynamic size analysis
 
Molecular sieve chromatography was per formed to determine
the hydrodynamic size of proteoglycans. Fractions were applied
to analytical Sepharose CL-2B columns (0.7 
 
3
 
 110 cm) equili-
brated in 4 M guanidine-HCl buffer with 0.5% Triton X-100.
Eluted fractions of 0.4 ml each were collected and assayed by liq-
uid scintillation counting. The elution position of free 
 
35
 
SO
 
4
 
 was
used as a marker for the total volume (V
 
t
 
) and the void volume
(V
 
0
 
) was determined by the elution position of [
 
3
 
H]DNA (22).
 
Glycosaminoglycan analysis
 
Proteoglycans were treated with 1 M sodium borohydride in
50 mM NaOH for 24 h at 45
 
8
 
C to release the glycosaminoglycan
chains. The reaction was terminated by neutralization with glacial
acetic acid (23). The free glycosaminoglycan chains then were ap-
plied to a Sepharose CL-6B column (0.7 
 
3
 
 65 cm) in 0.2 M Tris,
pH 7.0, with 0.2 M NaCl to determine chain length by size-exclu-
sion chromatography (22). The elution position of free 
 
35
 
SO
 
4
 
 was
used as a marker for the total volume (V
 
t
 
) and the void volume
(V
 
0
 
) was determined by the elution position of [
 
3
 
H]DNA. Molecu-
lar weights were assessed as previously described (24).
 
Free glycosaminoglycan chains
 
To isolate free glycosaminoglycans, cells were cultured as de-
scribed with the addition of 0.5 mM methyl 
 
b
 
-
 
d
 
-xylopyranoside
(xyloside), which serves as an artificial acceptor for the synthesis
of glycosaminoglycan chains (25). Xyloside was added to the cul-
ture medium at the time of exposure to the various experimen-
tal conditions, and in the presence of 
 
35
 
SO
 
4
 
. This results in the
synthesis of free glycosaminoglycan chains that are not attached
to core proteins. The free glycosaminoglycan chains generated
were assessed by cetyl pyridinium chloride (CPC) precipitation
(see below), and by size analysis on Sepharose CL-6B columns as
described. These free glycosaminoglycan chains also were used
in the gel mobility shift assay (see below).
 
Sulfate incorporation into proteoglycans
and glycosaminoglycans
 
CPC precipitation was performed to measure the incorpora-
tion of 
 
35
 
SO
 
4
 
 into glycosaminoglycan chains. Two 50-
 
m
 
l aliquots
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of 
 
35
 
SO
 
4
 
-labeled medium per tissue culture dish were spotted
onto filter paper, air dried, and then washed five times for 1 h in
1% CPC with 0.05 M NaCl. The filter paper was dried and the 
 
35
 
S
content of the precipitate was determined by liquid scintillation
counting (10, 23, 26).
 
SDS-PAGE chromatography
 
Proteoglycans were characterized by SDS-PAGE according to
the procedure of Laemmli (22, 23, 27) on 4 –12% gradient
slab gels with a 3.5% stacking gel. To estimate apparent mo-
lecular sizes, proteoglycan bands were compared with pre-
stained high molecular weight standards (Novex, San Diego,
CA) that were run in separate lanes. Gels were dried and visu-
alized on PhosphorImager screens (Molecular Dynamics,
Sunnyvale, CA).
 
LDL preparation
 
LDL were isolated from the plasma of normal human volun-
teers as described previously (28). Briefly, LDL (d 
 
5
 
 1.019–
1.063 g/ml) was separated from normal human plasma by pre-
parative ultracentrifugation in a Beckman (Palo Alto, CA) VTi
50 vertical rotor, and purified by sequential density gradient
ultracentrifugation (28, 29). Lipoprotein content was deter-
mined by the method of Lowry et al. (20). LDL was stored in the
dark at 4
 
8
 
C with 1 mM EDTA under nitrogen until used in the
gel mobility shift assay.
 
Gel mobility shift assay
 
The interaction between proteoglycans or free glycosamino-
glycan chains, synthesized under the various experimental con-
ditions described, with native human LDL was assessed by a
modified gel mobility shift assay (30). Native human LDL and
proteoglycans eluted from DEAE columns were prepared for use
in the gel mobility shift assay by extensive dialysis against mor-
pholinepropanesulfonic acid (MOPS) sample buffer (20 mM
MOPS, 140 mM NaCl, 5 mM CaCl
 
2
 
, 2 mM MgCl
 
2
 
, pH 7.4) at 4
 
8
 
C.
Increasing concentrations of LDL were mixed with a fixed
amount (approximately 1,500 dpm) of 
 
35
 
SO
 
4
 
-labeled proteogly-
cans, or free glycosaminoglycan chains, in MOPS sample buffer
for 1 h at 37
 
8
 
C. The samples then were applied to wells in 0.7%
(w/v) NuSieve agarose (FMC, Rockland, ME) at 4
 
8
 
C in MOPS
running buffer (20 mM MOPS, 2 mM CaCl
 
2
 
, 4 mM MgCl
 
2
 
, pH
7.2). In this assay proteoglycans or glycosaminoglycans that have
bound to the LDL are retained at the origin and unbound pro-
teoglycans or glycosaminoglycans migrate into the gel. The gels
were fixed in CPC [0.1% (w/v), in 70% ethanol] for 1 h, air
dried, and exposed to PhosphorImager screens. Analysis of the
images was performed with Opti-Quant software (Packard,
Downers Grove, IL). The amount of bound versus free proteogly-
cans or glycosaminoglycans in each lane was assessed and the per-
cent bound was calculated as the proportion of radioactivity re-
maining at the gel origin relative to the total radioactivity per lane.
Binding constants were calculated with the SAAM II modeling
program (SAAM Institute, Seattle, WA), using the Michaelis-
Menten equation, and statistical significance was determined by
paired 
 
t
 
-test.
 
LDL affinity chromatography
 
The binding of the total proteoglycan preparations to native
human LDL also was assessed by affinity chromatography to ob-
tain information regarding binding capacity. Metabolically la-
beled, protease inhibitor-containing culture medium from cells
exposed to physiologic glucose (5.6 mM) or glucosamine (12
mM) was extensively dialyzed against buffer consisting of 10 mM
HEPES, 20 mM NaCl, and 250 
 
m
 
M butylated hydroxytoluene,
and then applied to separate columns containing native human
Fig. 1. Glucosamine inhibits proteoglycan sulfate incorporation.
A: SMC exposed to physiological glucose (5.6 mM), high glucose
(25 mM) with or without azaserine (5 mM) or glucosamine (12
mM) for 24 h were metabolically labeled with 35SO4. The sulfate
incorporation of proteoglycans secreted into the culture medium
was analyzed by CPC precipitation as described in Research Design
and Methods, and is expressed as incorporated sulfate counts per
microgram of cell protein. Values are expressed as means 6 SD
relative to cells grown under physiological glucose conditions with-
out additives, which is expressed as 100% (n 5 7). B: SMC exposed
to the indicated concentrations of glucosamine for 24 h were met-
abolically labeled with 35SO4. The sulfate incorporation was ana-
lyzed by CPC precipitation, and is expressed as incorporated sul-
fate counts per microgram of cell protein. Values are expressed as
means 6 SD relative to cells grown under physiological glucose
conditions without additives, which is expressed as 100% (n 5 3).
C: SMC were exposed to glucosamine for the indicated time peri-
ods, and were metabolically labeled with 35SO4 for the last 8 h of
glucosamine exposure. The sulfate incorporation was analyzed by
CPC precipitation, and is expressed as incorporated sulfate counts
per microgram of cell protein. Values are expressed as means 6
SD relative to cells grown under low glucose conditions without ad-
ditives, at each time point, which is expressed as 100% (n 5 3).
Solid columns, physiological glucose (5.6 mM); diagonally
hatched columns, glucosamine at 0.12 mM; open columns, glu-
cosamine at 1.2 mM; horizontally hatched columns, glucosamine
at 12 mM. * P 5 0.01, ** P , 0.005 versus control.
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LDL bound to cyanogen bromide-activated Sepharose (31). The
columns were washed extensively with the same buffer. Binding
capacity was determined by calculating the radioactivity retained
by the LDL column after extensive washing, and was expressed
as a percentage of binding by control proteoglycans, which was
set at 100%.
 
RESULTS
To test the effects of glucosamine on total secreted pro-
teoglycans, the incorporation of radiolabeled sulfate into
proteoglycans was assessed after exposure of cells for 24 h
to glucosamine (12 mM). To assess the role of the hexo-
samine pathway, additional dishes were exposed to high
glucose (25 mM) or high glucose with azaserine. Glu-
cosamine supplementation (12 mM) resulted in a decrease
in proteoglycan sulfate incorporation (
 
Fig. 1A
 
), which was
the opposite of predicted. High glucose levels alone, or in
the presence of azaserine, had no effect on proteoglycan
sulfate incorporation (Fig. 1A). To further evaluate the
role of glucosamine in glycosaminoglycan synthesis, vascu-
lar smooth muscle cells were metabolically labeled with
 
35
 
SO
 
4
 
 in the presence of concentrations of glucosamine
ranging from 15 
 
m
 
M to 32 mM. A dose-dependent decrease
in proteoglycan sulfate incorporation was seen with glu-
cosamine concentrations greater than 2 mM (
 
P
 
 
 
<
 
 0.01)
(Fig. 1B). Time course studies performed by determining
sulfate incorporation at 8, 16, and 24 h of glucosamine ex-
posure showed that the decrease in sulfate incorporation
occurred as early as 8 h in the presence of 12 mM glu-
cosamine (
 
P
 
 
 
5
 
 0.01) (Fig. 1C). Cytotoxicity of glucosamine
was assessed by determination of cell culture medium
LDH activity, and by determination of total protein syn-
thesis by TCA precipitation of [
 
35
 
S]methionine-labeled
proteins. Cytotoxicity was found when cells were exposed
to azaserine, or to 32 mM glucosamine, but cytotoxicity was
not seen at lower concentrations of glucosamine (data not
shown). Despite the finding of cytotoxicity with azaserine,
proteoglycans synthesized in the presence of azaserine
were not different from those synthesized under control
conditions, suggesting that azaserine did not have a direct
effect on proteoglycan synthesis.
The decrease in glycosaminoglycan chain sulfate incor-
poration found in response to glucosamine could be due
to changes in the activity of sulfotransferases (15), or
could be due to shorter glycosaminoglycan chain lengths
with fewer sulfate-accepting groups. To assess glycosami-
noglycan chain length, the hydrodynamic size of secreted
proteoglycans was determined by molecular sieve chroma-
tography. Proteoglycans synthesized under control condi-
tions elute in two broad peaks: peak 1 (which contains
 
Fig. 2.
 
Glucosamine decreases the size of proteoglycans. A: Size-
exclusion chromatography was performed on proteoglycans syn-
thesized in the presence of physiological glucose (control, 5.6 mM;
open squares), high glucose (25 mM; solid squares), or physiologi-
cal glucose plus glucosamine (12 mM; solid circles). Analytical
Sepharose CL-2B columns were loaded with approximately 20,000
dpm. The dashed line indicates the 
 
K
 
av
 
 for peaks 1 (predominantly
versican) and 2 (predominantly biglycan and decorin) for pro-
teoglycans synthesized in the presence of physiological glucose lev-
els. The graph shown is representative of three separate experi-
ments. B: SDS-PAGE (3.5% stacking gel with 4 – 12% gradient
resolving gel) analysis of radiolabeled secreted proteoglycans syn-
thesized in the presence of the indicated concentrations of glu-
cosamine for 24 h. Each lane was loaded with 25,000 dpm. The gel
shown is representative of three separate experiments.
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cans synthesized in the presence of 12 mM glucosamine
were smaller [
 
K
 
av
 
 
 
<
 
 0.41, corresponding to a molecular
mass of 35 kDa (24)] than the chains cleaved from control
proteoglycans [
 
K
 
av
 
 
 
<
 
 0.35, corresponding to a molecular
mass of 45kDa (24)] (
 
Fig. 3
 
). In addition, the effect of glu-
cosamine supplementation on glycosaminoglycan synthe-
sis was assessed by directly investigating free glycosamino-
glycan chain synthesis. Free glycosaminoglycan chains
were synthesized by adding exogenous xyloside to the cul-
ture medium to act as an artificial acceptor for glycosamino-
glycan chain synthesis. This results in the synthesis of free
glycosaminoglycan chains that are not attached to core pro-
tein molecules (25). The free glycosaminoglycan chains
synthesized in the presence of glucosamine demonstrated a
dose-dependent decrease in sulfate incorporation (
 
Fig.
4A
 
), and a decrease in chain size as determined by molec-
Fig. 3. Glucosamine decreases the size of glycosaminoglycans.
Size-exclusion chromatography was performed on glycosaminogly-
cans cleaved from proteoglycans synthesized in the presence of
physiological glucose (5.6 mM; open squares) or glucosamine (12
mM; solid circles). Analytical Sepharose CL-2B columns were
loaded with approximately 20,000 dpm. The Kav for control gly-
cosaminoglycans corresponds to a molecular mass of 45 kDa, and
the Kav for glycosaminoglycans synthesized in the presence of glu-
cosamine corresponds to a molecular mass of 35 kDa, using the
standard curve of Wasteson (24). The graph shown is represent-
ative of three separate experiments.
predominantly versican) with a Kav of 0.28, and peak 2
(which contains a mixture of biglycan and decorin),
which has a Kav of 0.62 (Fig. 2A) (22, 23). There was no
difference in the Kav of peak 1 or peak 2 between pro-
teoglycans synthesized in the presence of physiologic or
high glucose levels (Fig. 2A), or in the presence of high
glucose with azaserine (data not shown). However, the
proteoglycans synthesized in the presence of glucosamine
(12 mM) were smaller (Kav of 0.36 and 0.65, respectively,
for peaks 1 and 2) (Fig. 2A). To confirm these data, the
apparent molecular size of glucosamine-modified pro-
teoglycans was assessed by SDS-PAGE. A dose-dependent
increase in mobility of two of the major proteoglycans
produced by these cells, biglycan and decorin, was seen in
the presence of glucosamine concentrations between 2
and 32 mM (Fig. 2B). No difference in proteoglycan size
was seen between proteoglycans synthesized in the pres-
ence of control or high glucose levels (Fig. 2B), or in the
presence of glucosamine concentrations less than 2 mM
(data not shown). These experiments suggest that there is
no change in proportion of chondroitin sulfate, dermatan
sulfate, and heparan sulfate proteoglycans in the secreted
proteoglycans synthesized in the presence of glucosamine.
It previously has been reported that there is a change in the
proportion of vascular proteoglycans in diabetes, with an
increase in chondroitin sulfate and dermatan sulfate pro-
teoglycans and a relative decrease in heparan sulfate
proteoglycans (4).
To examine the effect of glucosamine supplementation
on the glycosaminoglycan components of the proteogly-
cans, proteoglycans synthesized in the presence of glu-
cosamine (12 mM) or synthesized under control conditions
were treated with sodium borohydride to release their gly-
cosaminoglycan chains. The size of these released chains
was then determined by molecular sieve chromatography.
The glycosaminoglycan chains cleaved from proteogly-
Fig. 4. Free glycosaminoglycans synthesized in the presence of
glucosamine are smaller and less sulfated than control glycosami-
noglycans. A: SMC were exposed to xyloside (0.5 mM) with the in-
dicated concentrations of glucosamine for 24 h and were metaboli-
cally labeled with 35SO4. The sulfate incorporation of the free
glycosaminoglycans secreted into the culture medium was analyzed
by CPC precipitation, and is expressed as a ratio of incorporated
sulfate counts per microgram of cell protein. Values are expressed
as means 6 SD relative to free glycosaminoglycans synthesized in
the presence of physiological glucose (control), which is expressed
as 100%. * P , 0.001 versus control (n 5 3). B: Size-exclusion chro-
matography was performed on free glycosaminoglycans synthesized
in the presence of physiological glucose (5.6 mM; open squares) or
glucosamine (12 mM; solid circles). Analytical Sepharose CL-2B
columns were loaded with approximately 20,000 dpm. The Kav for
control glycosaminoglycans corresponds to a molecular mass of 32
kDa, and the Kav for glycosaminoglycans synthesized in the pres-
ence of glucosamine corresponds to a molecular mass of 15 kDa,
using the standard curve of Wasteson (24). The graph shown is re-
presentative of three separate experiments.
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ular sieve chromatography (Fig. 4B). These data demon-
strate that glucosamine supplementation directly affects
glycosaminoglycan chain synthesis.
To determine whether the proteoglycans synthesized by
cells exposed to glucosamine had a decrease in LDL-binding
affinity consistent with their smaller size, a modified gel
mobility shift assay was performed. In this assay, proteogly-
cans that have bound LDL are retained at or near the ori-
gin, whereas unbound proteoglycans migrate into the gel
(30). Analysis and quantification of the binding pattern
allow determination of binding affinity constants. Repre-
sentative gel mobility shift assays for proteoglycans synthe-
sized under control conditions (Fig. 5A) or with supple-
mental glucosamine (Fig. 5B), and the binding curves
generated (Fig. 5C), show a significant decrease in LDL-
binding affinity for proteoglycans synthesized in the pres-
ence of 12 mM glucosamine. Analysis of the gels shows
that proteoglycan-lipoprotein complexes form at higher
LDL concentrations when the proteoglycans are synthe-
sized in the presence of glucosamine (Fig. 5B) compared
with control proteoglycans (Fig. 5A). By using SAAM II
modeling we determined that proteoglycans synthesized in
the presence of 12 mM glucosamine had a lower binding
affinity (Kd of 79 mg of LDL per ml, or 1.44 3 1027 M LDL,
assuming a molecular mass of 550,000 kDa for apoB) than
control proteoglycans (Kd of 30 mg of LDL per ml or 5.45 3
1028 M LDL; P , 0.05). No differences in LDL-binding af-
finities were seen for proteoglycans synthesized in the
presence of high glucose levels (25 mM), or high glucose
with azaserine, compared with control proteoglycans (data
not shown).
To analyze the LDL-binding capacity of proteoglycans
synthesized under control conditions or in the presence
of glucosamine, LDL affinity chromatography was per-
formed. Equal aliquots (approximately 500,000 dpm) of
secreted proteoglycans synthesized in the presence of low
glucose (5.6 mM), or in the presence of low glucose plus
glucosamine (12 mM), were applied to columns contain-
ing native human LDL. The capacity of the proteoglycans
to bind to the LDL was determined by calculating the rela-
tive retention of the radiolabeled proteoglycans. Proteo-
glycans synthesized in the presence of glucosamine (12
mM) had significantly lower binding capacity than control
proteoglycans (P , 0.001) (Fig. 6). Thus, proteoglycans
synthesized in the presence of glucosamine have reduced
LDL-binding affinity and binding capacity compared with
control proteoglycans.
To determine whether the effect of glucosamine supple-
mentation on the LDL-binding affinity of proteoglycans
was mediated through their shortened glycosaminoglycan
chains, the binding affinity of free glycosaminoglycan chains
initiated on xyloside (25) was determined by the modified
gel mobility shift assay. Free glycosaminoglycans synthesized
in the presence of glucosamine (12 mM) had a lower LDL-
binding affinity (Kd of 772 mg LDL per ml or 1.4 3 1026 M
LDL) compared with modified free glycosaminoglycans
synthesized under control conditions (Kd of 557 mg of LDL
per ml or 1.0 3 1026 M LDL) (Fig. 7). The lower binding
affinity for free glycosaminoglycans compared with intact
proteoglycans is likely due to their much smaller size. These
data demonstrate that the effect of glucosamine supple-
mentation on decreasing the LDL-binding affinity of pro-
Fig. 5. Proteoglycans synthesized in the presence
of glucosamine have reduced LDL-binding affinity
compared with control proteoglycans. Equal
amounts of total secreted proteoglycans (approxi-
mately 1,500 dpm) from control proteoglycans (A)
or proteoglycans synthesized in the presence of 12
mM glucosamine (B) were incubated with the indi-
cated concentrations of native human LDL under
physiological conditions for 1 h. Samples were then
applied to agarose gels and electrophoresed, as de-
scribed in Research Design and Methods. Proteogly-
cans that have been bound by LDL are retained at
or near the origin whereas free proteoglycans mi-
grate into the gel. Binding curves (C) were calcu-
lated by expressing the percentage of proteoglycans
bound as a ratio of total radioactivity in each lane.
The lower Kd for control proteoglycans (open
squares; Kd 5 LDL at 30 mg/ml or 5.45 3 1028 M
LDL) indicates higher binding affinity than for pro-
teoglycans synthesized in the presence of glu-
cosamine (solid circles; Kd 5 LDL at 79 mg/ml or
1.44 3 1027 M LDL) (P , 0.05). Gels shown are re-
presentative of three separate experiments.
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teoglycans is mediated, at least in part, through the effects
of glucosamine on the glycosaminoglycan chains.
DISCUSSION
The data presented demonstrate that under these ex-
perimental conditions extracellular proteoglycans synthe-
sized in the presence of glucosamine are smaller, with
shorter glycosaminoglycan chains. The proteoglycans syn-
thesized in the presence of glucosamine have a lower
binding affinity and capacity for LDL compared with pro-
teoglycans synthesized in the presence of physiological
glucose (5.6 mM, or control). However, proteoglycans syn-
thesized in the presence of high glucose levels such as
seen in diabetes, or in the presence of azaserine to inhibit
glucose from entering the hexosamine pathway, do not
differ from control proteoglycans in size, sulfate incorpo-
ration, or LDL-binding affinity. Azaserine is a glutamine
analog that acts as a nonspecific inhibitor of GFAT. Al-
though it is unstable in cell culture medium over long
time periods after a single dose, azaserine is commonly
used in this way to test the role of the hexosamine pathway
(19). Because there were no differences between pro-
teoglycans synthesized in the presence of high glucose,
high glucose with azaserine, or control, this suggests that
the flux of glucose through the hexosamine pathway is
maximal at low glucose concentrations in this cell type.
Therefore, inhibition of GFAT by azaserine does not have
any effect on proteoglycan synthesis.
Glycosaminoglycan chains cleaved from proteoglycans
synthesized in the presence of glucosamine supplementa-
tion were shown to be smaller than glycosaminoglycan
chains cleaved from proteoglycans synthesized under con-
trol conditions. Free glycosaminoglycan chains synthe-
sized in the presence of glucosamine also were shorter,
and bound LDL with lower binding affinity than free gly-
cosaminoglycan chains synthesized under control condi-
tions. This suggests that the glucosamine effect is being
mediated on the carbohydrate moiety of proteoglycans,
and is not due to a toxic effect on core protein synthesis;
neither is it a limitation of core protein molecule availabil-
ity to accept glycosaminoglycan chains during synthesis.
The decreased sulfate incorporation seen in the presence
of glucosamine is likely the result of shorter chain length
with fewer sulfate-accepting groups, although a decrease
in the sulfate-to-carbohydrate ratio cannot be ruled out by
these experiments. These alterations in proteoglycans were
seen rapidly: time course studies indicated that the inhibi-
tion of proteoglycan synthesis in the presence of glu-
cosamine occurred within 8 h of exposure to glucosamine.
This suggests that the effect of glucosamine is due to alter-
ations in proteoglycan synthesis rather than to changes in
proteoglycan degradation. The effect of glucosamine on
proteoglycans is not due to cytotoxicity. Assays of cell culture
medium LDH activity showed that there was no toxicity seen
at glucosamine levels less than 12 mM. Further, total cell
protein synthesis was decreased only in the presence of high
levels of glucosamine supplementation (32 mM). Several
groups have reported increased glycosaminoglycan synthe-
sis with glucosamine supplementation in chondrocytes (12,
13), fibroblasts (32), and mesangial cells (19). However, the
methods for detecting glycosaminoglycan synthesis vary
widely between these reports and the present study, which
could account for the differences seen between these
present studies. Alternatively, the effect of glucosamine on
glycosaminoglycan synthesis may be tissue specific, with in-
Fig. 6. Proteoglycans synthesized in the presence of glucosamine
have reduced LDL-binding capacity. Proteoglycans (1 million dpm)
synthesized in the presence of physiological glucose (5.6 mM; open
column) or 12 mM glucosamine (solid column) were dialyzed
against 10 mM HEPES with 20 mM NaCl and 250 mM butylated hy-
droxytoluene, and then were applied to separate LDL-Sepharose af-
finity columns. The binding capacity is determined by subtracting
the disintegrations per minute eluted from the columns after ex-
tensive washing with 10 mM HEPES with 20 mM NaCl from the dis-
integrations per minute loaded. Values are expressed as means 6
SD relative to the binding of proteoglycans synthesized under con-
trol conditions, which is expressed as 100%. * P , 0.001 versus con-
trol (n 5 4).
Fig. 7. Free glycosaminoglycans synthesized in the presence of
glucosamine have lower LDL-binding affinity than control gly-
cosaminoglycans. Equal amounts of labeled glycosaminoglycans
(approximately 1,500 dpm) synthesized under control conditions
(open squares) or in the presence of 12 mM glucosamine (solid cir-
cles) were incubated with indicated concentrations of native hu-
man LDL under physiological conditions for 1 h. Samples then
were applied to agarose gels and electrophoresed. Glycosaminogly-
cans that have been bound by LDL are retained at or near the ori-
gin whereas free glycosaminoglycans migrate into the gel. The
binding curves were calculated by expressing the percentage of gly-
cosaminoglycans bound as a ratio of total radioactivity in each lane.
The lower Kd for control glycosaminoglycans (Kd 5 557 mg of LDL
per ml or 1.0 3 1026 M LDL) indicates a higher binding affinity
than for glycosaminoglycans synthesized in the presence of glu-
cosamine (Kd 5 772 mg of LDL per ml or 1.4 3 1026 M LDL). The
graph shown is representative of two separate experiments.
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creased glycosaminoglycan synthesis in some tissues and
decreased glycosaminoglycan synthesis in others. Further
studies of the effect of glucosamine on glycosaminoglycan
synthesis in various cell types are warranted.
One explanation for the lack of effect of high glucose
on proteoglycan synthesis may be that vascular smooth
muscle cells in vitro have glucose metabolism that differs
from glucose metabolism of vascular smooth muscle cells
in vivo. Several groups have previously reported that glu-
cose metabolism by cultured cells varies depending on the
availability of other oxidative substrates (33–35). Suzuki
et al. (36) reported that .90% of glucose consumed by
smooth muscle cells in vitro under both physiological and
high glucose (25 mM) conditions is converted to lactate
and secreted. They speculate that the high rate of anaero-
bic glycolysis by smooth muscle cells in vitro may be re-
sponsible for the relative insensitivity to high glucose levels
that they observed. In addition, others have reported that
high glucose levels can modify the ability of cytokines to
affect proteoglycan synthesis (19, 37). It is conceivable
that the effect of high glucose on proteoglycan synthesis
by vascular smooth muscle cells in vivo may be different
from that presented in this in vitro study.
Glucosamine is a nutritional supplement commonly
claimed to alleviate joint pain in osteoarthritis. It has been
available in Europe for many years, but is now gaining
popularity in the United States as an over-the-counter
remedy for arthritis. Despite the widespread and increas-
ing use of glucosamine, little is known concerning its
safety or efficacy. Glucosamine is a nutritional supplement
and therefore the authority of the Food and Drug Admin-
istration to regulate it is now severely limited (38). There
have been relatively few trials of glucosamine use in hu-
mans, and those that have been published are studies that
examined the efficacy of glucosamine in the relief of joint
pain (39). There have been no reported trials of long-
term glucosamine use, and its long-term safety is unknown.
Glucosamine consumption by the American public is on
the rise (40), in part due to favorable, but scientifically in-
conclusive, reports of glucosamine therapy for arthritis
symptoms (41). Glucosamine is available as an over-the-
counter oral supplement, has few overt side effects, and is
relatively inexpensive. Studies suggest that glucosamine
supplementation may have significant benefits on osteoar-
thritis (11); however, the mechanisms underlying this ef-
fect are not yet known. The current recommended oral
dose for humans is 1,500 mg of glucosamine daily, taken in
divided doses. Setnikar and colleagues (42–44) have pub-
lished several reports on the pharmacokinetics of glu-
cosamine in rats, dogs, and humans. In both humans and
rats, oral administration of radiolabeled glucosamine re-
sults in absorption of more than 90% of the ingested dose.
Free glucosamine is not detectable in plasma, but after a
lag time of 1–2 h the radioactivity appears in plasma pro-
teins (42, 44). Glucosamine appears to undergo a signifi-
cant first-pass effect in the liver, which metabolizes a signifi-
cant proportion of the dose to CO2, water, and urea (44).
Olszewski, Szostak, and McCully (45) measured plasma glu-
cosamine levels in survivors of recent myocardial infarc-
tions and healthy control subjects by ion-exchange chroma-
tography. They report levels of total glucosamine in the 4 mM
range, and levels of free glucosamine (measured in depro-
teinized hydrolyzed plasma) in the range of 400 mM.
The majority of in vitro studies have used doses in the
range of 1–12 mM glucosamine (16, 19, 46). Thus, the con-
centrations of glucosamine used in our study are compati-
ble with the current literature. Plasma glucosamine levels
are not detectable in humans after oral ingestion of sup-
plements, but are likely to be in the micromolar range
(44, 45). However, no evidence of cytotoxicity was found
at this glucosamine concentration, and the concentration
of glucosamine at the level of the artery wall is unknown.
Our studies demonstrate that proteoglycans synthesized
in the presence of various concentrations of glucosamine
demonstrate a dose-dependent decrease in sulfate incor-
poration with glucosamine concentrations from 2 through
32 mM. The potential biological implications for these
data is significant, if the same effects are confirmed in
vivo. Given the vast clinical burden imposed by atheroscle-
rotic disease, any potential atheroprotective interventions
are of significant interest, and further studies into the role
of glucosamine in vascular biology are needed.
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